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Substance abuse, especially opioid misuse is a growing public health issue. Opioid 
dependency affects not only the individual who is dependent on opioids but negatively 
impacts the family unit, the community, and society as a whole. Opioid use in the 
prenatal period can have devastating effects on both the mother and the fetus. The 
purpose of this paper is to perform a secondary analysis of the effectiveness of behavioral 
modification in reducing relapse rates and improving compliance of treatment regimen in 
opioid dependent pregnant women who are being managed in a FamilyCare Health 
Center  in West Virginia. The transtheoretical model was used as a framework to 
determine participants’ behavioral readiness to change. The Stetler model was used to 
evaluate outcomes and goal achievement. The sample consisted of pregnant opioid 
dependent women over r the age of 18 (including emancipated minors) who have 
participated in the Subutex-assisted program at three FamilyCare Health Center  in West 
Virginia. The analysis consisted of a secondary source of data with a review of medical 
records to determine if behavioral modification contributed to a reduction in relapse rates 
and improved compliance with treatment regimen in opioid dependent pregnant women 
who are participants in a Subutexassisted program. The results showed behavioral 
modification does contribute to a reduction in relapse rates in the target population. The 
information obtained from this analysis can be used to assist healthcare providers in 
revising or modifying existing programs and help to design future programs that 
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Section 1: Nature of the Project 
The Introduction 
Opioid dependence and misuse is a growing global public health issue (Park, 
Meltzer-Brody, & Suzuki, 2012). In the United States almost 3 million Americans are 
affected by opioid use disorders (Haddad, Zelenev, & Altice, 2013). Opioid dependency 
affects all ages. According to national surveys, 90% of women who are classified as 
opioid dependent are of child-bearing age (Park et al., 2012).  In 2010, the National 
Survey on Drug Use and Health reported approximately 4.4% of pregnant respondents 
admitted to the use of illicit drugs in the last 30 days (American Congress of 
Obstetricians and Gynecologists [ACOG], 2012).  
Opioid drug use, especially chronic use in pregnancy, is associated with poor 
maternal health and potentially devastating negative effects on the fetus. Up until 
recently, opioid dependency in the pregnant population had been managed with 
methadone. Buprenorphine (Subutex) has recently emerged as an alternative to the 
traditional opioid–assisted therapy using methadone (Park et al., 2012). Because the use 
of Subutex is a relatively new practice in managing opioid dependency in the pregnant 
population, research is limited. As with any substance use disorder, relapse and 
noncompliance are challenges that both the client and healthcare team encounter. 
Therefore the DNP project focused on the secondary analysis of using behavioral 
modification to reduce the incidence of relapse and improve compliance with prescribed 
Subutex-assisted treatment regimen in opioid dependent pregnant women who are being 
managed in a federally funded FamilyCare Health Center  in West Virginia. A secondary 
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analysis and evaluation of the effectiveness of behavioral modification in improving 
compliance and minimizing relapse rates (having less than a 5% relapse rate) in pregnant 
women who are enrolled in the Subutex program at the family care clinic was done. The 
practicum site collected all medical records for review, kept them in a central locked 
location, and used a numbering system to maintain confidentiality of patients.  
Problem Statement 
Opioid use, in the form of heroin or opioid analgesic medications, can have 
adverse effects when used in pregnancy. Substance abuse while pregnant can have 
deleterious long term adverse effects that start in utero and continue over one’s lifespan 
(National Institute on Drug Abuse [NIDA], 2011). In 2008 to 2009, NIDA conducted a 
survey on drug abuse among pregnant women in the United States. The sample included 
pregnant women between the ages of 15 to 44 years of age. Results of the study revealed 
pregnant women between the ages of 15-17 years of age reported the greatest substance 
use (NIDA, 2011). In addition, these pregnant adolescents had higher rates of illicit 
substance abuse (15.8% or 14,000 women) than their counterparts who were not pregnant 
(13.0% or 832,000 women) (NIDA, 2011).  
The American College of Gynecologists and Obstetricians (ACOG) conducted a 
study on drug use in the pregnant population and reported 0.1% of pregnant women had 
reportedly used heroin in the last month of pregnancy and 1% of respondents admitted to 
the nonmedical use of opioid analgesic medications, making substance abuse in 
pregnancy a priority issue (ACOG, 2012).  Treating opioid dependency in pregnant 
women requires a multidisciplinary team approach that must be supported by evidence-
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based interventions and treatment. Substance use and abuse, especially the use of opioids 
during pregnancy is associated with adverse maternal and fetal outcomes, as well as 
negative societal and economic consequences. Due to limited research on opioid 
dependence in pregnant women who are enrolled in a Subutex-assisted treatment 
program, little evidence is available to analyze the effectiveness of behavioral 
modification in conjunction with Subutex-assisted treatment programs.  
Purpose Statement 
The purpose statement for this project is: The secondary analysis of the use of 
behavioral modification to reduce relapse in opioid dependent pregnant women over the 
age of 18 years of age as well as emancipated minors.  The purpose of the project is to 
evaluate the effectiveness of behavioral modification in promoting positive lifestyle 
changes in the opioid dependent pregnant women  over the age of 18 years of age  as well 
as emancipated minors.  who are enrolled in a Subutex-assisted treatment program in a 
FamilyCare Health Center in West Virginia. Positive lifestyle changes in this population 
will consist of these women not using illicit drugs and having less than a 5% relapse rate.  
Purpose Objectives 
Objectives can be defined as measurable, realistic, time oriented statements that 
are in alignment with the project’s goals (Hodges & Videto, 2011). Objectives provide 
the project team with a clear understanding of the goals and expectations of the initiative 
and are linked to the evaluation method. This project has three clear objectives: (a)  
provide a secondary analysis of data, (b) evaluate the effectiveness of behavioral 
modification therapy in minimizing relapse rates in opioid dependent pregnant females 
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over the age of 18 years of age (including emancipated minors) who have been enrolled 
in a Subutex-assisted treatment program, and (c) report the results of the analysis to the 
team at the clinic. 
Significance to Practice 
Opioid use and abuse in the pregnant population involves potentially harmful 
maternal and fetal consequences, as well as a higher incidence of maternal, fetal, and 
neonatal morbidity (Wong, Ordean, & Kahon, 2011).  Pregnant women who have a 
substance abuse problem may be reluctant to seek prenatal care, leading to poor outcomes 
(Pinto et al., 2012; Winklbaur et al.,  2008; Wong et al., 2011) Confounding factors 
associated with substance abuse, especially opioid dependency, in pregnant women that 
can exacerbate poor maternal and fetal outcomes include a higher incidence of engaging 
in negative lifestyle behaviors, such as poor nutrition, the use of other substances, for 
example alcohol and tobacco use, depression, domestic violence, and a higher rate of 
infectious diseases, such as HIV/AIDS, hepatitis, and sexually transmitted infections 
(Anderson, Roux, & Pruitt, 2002; Wong et al., 2011).  
Spontaneous abortions, preeclampsia, preterm labor, placental insufficiency, 
premature rupture of membranes leading to intrauterine infection, and abruptio placenta 
are some of the serious medical consequences associated with opioid dependence in 
pregnancy (Park et al., 2012; Pinto et al., 2010). Relapse during pregnancy is associated 
with periods of intoxication and withdrawal predisposing the mother and fetus to a 
vicious cycle that may ultimately lead to death (ACOG, 2012). Following delivery, these 
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mothers are at a high risk for relapse, therefore continuation with drug addiction 
programs is essential (Park et al., 2012).   
The transtheoretical model of change (TTM) and the Stetler model will be used to 
guide the project. The TTM is a popular model that can be used to support intentional 
behavioral change and is applicable to a variety of populations, behaviors, and settings 
(Hodges & Videto, 2011). This model integrates the principles and process of change to 
influence intentional behavioral change. Behavioral change proceeds through a series of 
stages with the application of diverse interventions and strategies to influence behavior 
modification. Resistance to change is managed and relapse is prevented. 
The Stetler model is a practice oriented model that utilizes the principles of 
change to introduce new evidence into clinical practice. The Stetler model is divided into 
five phases that utilize the decision making process to determine if evidence supports a 
practice change (Stetler, 2001). This model supports the project by implementing 
findings into the practice setting to determine if behavioral modification is effective in 
reducing relapse rates in opioid dependent pregnant women. Both of these models will be 
discussed in detail in Section 2.  
Reduction in Gaps 
Due to the limited number of studies conducted on opioid dependency during 
pregnancy, long-term effects of opioids on the fetus cannot be determined sufficiently, 
especially the effects of Subutex. However, infants born to opioid dependent mothers 
have a higher risk of prematurity, intrauterine growth retardation, birth defects, and 
neonatal abstinence syndrome (NAS) (ACOG, 2012; Kraus et al., 2011). Due to limited 
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research, the severity and duration of NAS impacted by methadone or Subutex is unclear; 
however, infants born to mothers on methadone or Subutex will exhibit signs of 
withdrawal with varying degrees of severity (Park et. al., 2012). Therefore, it is 
imperative that opioid dependent pregnant women seek replacement therapy early in the 
prenatal period.   
Treating patients, pregnant and non-pregnant, who have substance and drug 
addiction issues, places an added burden on an already drained healthcare system. 
Numerous indirect and direct costs are associated with treating substance use in the 
prenatal and postnatal periods (Wong et. al., 2011). Healthcare costs are associated with 
an increased incidence of social cost and comorbidities, such as: infectious disease, HIV 
and hepatitis, loss of work due to premature birth and other maternal complications, as 
well as increased cost associated with treatment for both mother and infant (Haddad 
et.al., 2013).  
Despite best efforts, relapse, resistance, and noncompliance with treatment are 
issues that challenge practitioners. The NIDA (2008) conducted a survey on drug 
addiction and reported a 40–60% relapse rate amongst users. Drug addiction is 
characterized by periods of abstinence followed by intermittent relapse. Despite effective 
pharmacological management of drug addiction, relapse rates remain high among opioid 
dependent clients (Tkacz, Severt, Cacciola, & Ruetsch, 2012). Due to high relapse rates, 




A number of factors can influence the probability of relapse. Intrapersonal factors 
that may hinder treatment include lack of motivation to change, inability to manage 
stress, poor self esteem, and inability to manage interpersonal conflicts with family 
members and others (Jones, 2013; Parks et. al., 2011; Tkacz et. al., 2012). Environmental 
factors that may hinder treatment include peer pressure, partners who have problems with 
substance abuse, and a number of environmental stimuli that make compliance with 
treatment overwhelming (Jones, 2013; Parks et. al., 2011; Tkacz et. al., 2012). Relapse 
does not point to failure but indicates a need for practitioners to adjust current treatment 
modalities to meet the needs of the patient or seek alternative treatments.  
Project Question 
In writing a project question to explore the effectiveness of therapy, the problem, 
intervention, comparison, outcome, and time formula, also known as the PICOT, was 
utilized (Riva et. al., 2012). The PICOT question is a formula that is used to assist in 
identifying outcomes that are dependent on specific interventions or actions (Riva et. al., 
2012). Evidence must either support or refute the intervention that influences the project.  
Project Question:  What is the relationship between behavioral modification in 
combination with Subutex-assisted therapy and relapse rates in opioid dependent 
pregnant women over the age of 18 years as well as emancipated minors?  
PICO: In pregnant opioid dependent women  over 18 years of age does behavioral 
modification drug abuse counseling in combination with Subutex-assisted therapy, 
compared to no drug abuse counseling, reduce relapse rates by more than 5% in the 
prenatal period?   
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Population: pregnant opioid dependent women  over 18 years of age. 
Intervention: behavioral modification drug abuse counseling with Subutex-
therapy. 
Comparison: no drug abuse counseling. 
Outcome: reduce relapse rates by more than 5% in the prenatal period. 
A secondary analysis was the preferred approach to achieve the project’s goals 
and objectives and answer the PICO question. A descriptive correlational study design 
was used. This design examined the relationships between study variables without using 
manipulation or control (Burns & Grove, 2009). In this project I collected and analyzed 
data to determine if the current treatment regimen is effective in reducing relapse in the 
target population. The identity of study participants remained anonymous and I had no 
contact with the subjects.  
Evidence-Based Significance 
Substance abuse and dependency is creating a negative impact on society welfare. 
In 2004, 7.9% of the American population admitted to current drug use (Morgan & 
Crane, 2010). In the United States, 59,000 deaths have been linked to drug misuse and 
annually over 40 million injuries or illnesses are associated with substance abuse (Cox, 
Ketner, & Blow, 2013). The cost of substance abuse and dependency is taking a toll on 
society. The negative financial implications from drug abuse are seen in escalating crime 
rates, increased healthcare costs, an increase in government assistance programs, high 
unemployment rates, and decreased work productivity (Morgan & Crane, 2010). The cost 
of drug abuse has risen in the United States since 1992 by 5.9% annually reaching an all 
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time high of approximately $180 billion in 2002  (Morgan & Crane, 2010). These 
statistics have led program planners, lawmakers, healthcare providers, and researchers to 
search for methods and design programs to minimize and reduce the negative impact of 
drug addiction on society.  
In addition, drug addiction has a negative impact on the individual, family unit, 
and the community. Substance misuse and addiction are sources of conflict within 
families and marriages. Families are being split apart due to drug addiction and misuse of 
substances. According to longitudinal prospective studies on marriage and substance use 
in both older and younger couples, frequent substance use was  a predictor of subsequent 
divorce (Collins, Ellickson, & Klein, 2007). Drug and substance misuse during 
pregnancy can have devastating effects on the unborn fetus. Despite a multidisciplinary 
approach to prenatal care, research indicates higher incidences of adverse obstetric and 
perinatal complications in women who abuse substances (Pinto et. al., 2010). 
Researchers have supported the use of various strategies to help reduce and treat 
drug addiction others (Jones, 2013; Parks et. al., 2011; Tkacz et. al., 2012). Behavioral 
modification in combination with the use of synthetic opioids, such as Subutex, have 
proven to be effective in minimizing relapse rates in the opioid dependent population 
(Parks et. al., 2012). Therefore, the benefits of treatment outweigh the societal and costly 
implications of drug addiction (U.S. Department of Health and Human Resources, 2009). 
Implications for Social Change 
As previously stated, drug addiction and substance abuse negatively impacts 
society.  Social change is defined as “any fundamental alteration in (a) the structure of 
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existing relationships of a society or parts of a society, (b) the processes or common 
practices used in everyday life, (c) population composition, and (d) the basic values, 
ideas, and ways of thinking that prevail in a society” (Naughton, 2008, p. 15). Preventing 
and treating substance abuse disorders can have a major impact on society. Therefore, 
drug prevention programs must foster a supportive environment that promotes health-
related quality of life outcomes and engages clients to become active participants in their 
treatment regimen (Villeneuve et. al., 2006). This project can contribute to the 
advancement of policy by emphasizing the importance of programs that focus on drug 
prevention and helping clients to overcome the devastating cycle of drug abuse and 
dependency.  
Doctoral prepared nurses can lead the journey in designing programs that meet the 
needs of the target population. Therefore the purpose of this project is to impact social 
change by evaluating the effectiveness of behavioral modification as an adjunct treatment 
to Subutex therapy. Integrating evidence-based practices into the clinical setting will 
bridge the gap between theory and practice and significantly improve health outcomes. 
(White & Dudley-Brown, 2012). 
Definition of Terms 
To provide a clear understanding of terms that are used throughout this project 
proposal, a list of defining terms used will be provided: 
Conceptual Definitions: 
Abstinence   practice of not doing or having something that is wanted or enjoyed, 
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Behavioral Modification  term for the use of empirically demonstrated behavior change 
techniques to increase or decrease the frequency undesired behavior, such as substance 
misuse,  
 
Contingency Management  systematic reinforcement of desired behaviors and the 
withholding of reinforcement or punishment of undesired behaviors, 
 
Relapse  to fall or slide back into a previous state 
(Morrison-Valfre, 2011).  
________________________________________________________________________ 
 
Definitions of Medications to Treat Opioid Dependency in Pregnancy: 
Buprenorphine  synthetic opioid used to treat opioid dependency, 
 
Methadone  synthetic opioid, 
 
Opioid  psychoactive chemical that has properties similar to Morphine or other opiate in 
its pharmacological effects, 
 
Subutex  trade name for buprenorphine  
 
(Morrison-Valfre, 2011).  
 
Other Definitions: 
Abruptio Placenta  premature separation of the placenta from the uterus, 
 
Fullterm Birth  baby born 37+ completed weeks of pregnancy, 
 
Intrauterine Growth Retardation  poor growth of a fetus while in utero, 
 
Neonatal abstinence Syndrome (NAS)  group of problems that occur in a newborn who 
was exposed to addictive illegal or prescription drugs while in utero, 
 
Placental Insufficiency  insufficient blood flow to the placenta during pregnanc,y 
 
Preeclampsia  medical condition in pregnancy characterized by high blood pressure and 
increased amounts of protein in the urine, 
 




Premature Rupture of Membranes  condition in pregnancy where there is a rupture of the 
amniotic sac membrane and chorion before 37 completed weeks of pregnancy, 
 
(Leifer, 2011).  
 
Assumptions and Limitations 
 
Assumptions 
During pregnancy, behavioral modification interventions in combination with 
Subutex may reduce relapse in opiod dependent women. Literature supports the 
assumption that pregnancy is an opportune time to motivate expectant mothers. Improved 
healthcare outcomes are likely when interventions are employed to motivate lifestyle 
changes. Literature indicates medication alone may not be sufficient to minimize and 
prevent relapse rates in drug addiction (ACOG, 2012). Therefore, it is assumed that 
implementing behavioral modification in combination with Subutex will lead to 
improved outcomes for both expectant mother and the unborn child.  
Limitations 
The most apparent limitation in the study was related to the methodology. 
Initially, the sample size of the population was expected to be around 100. However, as 
the project evolved, the sample size was reduced to 43 participants. Due to the small 
sample size, generalizablity may have been affected.  
 Summary 
In summary, substance misuse and opioid dependency is becoming a growing 
public health concern. Opioid abuse and dependency during pregnancy may lead to both 
maternal and fetal complications. Programs need to be designed to minimize relapse rates 
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during the prenatal period and postnatal periods. This project will evaluate the 
effectiveness of using behavioral modification in combination with Subutex therapy in 
existing programs affiliated with three FamilyCare Health Centers located in West 
Virginia. Section 2 will show the relationship between existing literature and the use of 







Section 2: Review of Literature and Theoretical and Conceptual Framework 
Introduction 
Opioid use while pregnant can have devastating effects on both the mother and 
unborn child. Pregnancy is a opportunity to introduce healthcare interventions to elicit 
behavioral change and modification. This purpose of this project is to determine if a 
relationship exists between behavioral modification and the reduction of relapse rates in 
opioid dependent pregnant women and to evaluate the effectiveness of an existing 
program in meeting the needs of this population. A review of existing literature focusing 
on current studies that have been published in professional journals and documentation 
from government agencies that conducts research is significant to providing information 
about the topic under review. This section includes a review of scholarly evidence from 
literature sources to support the assumption of opioid dependency in pregnancy and the 
use of behavioral modification to reduce relapse rates, as well as the integration of 
theoretical frameworks to guide the project. The review of literature includes both 
specific literature sources to support the use of Subutex-assisted therapy and general 
literature sources to validate the use of behavioral modification and contingency 
management in minimizing relapse in the target population.  
Literature Search Strategy 
Several strategies were used to search and locate current, relevant sources of 
literature. Several databases were used to locate current research and literature on opioid 
dependency in pregnancy. In searching databases located in the library at Walden 
University, nursing was the chosen subject. The nursing and health databases were 
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chosen, specifically CINAHL Plus with Full Text, Nursing & Allied Health Source, and 
MEDLINE with Full Text. Current, within the last 5 years, peer reviewed studies were 
chosen for review. Key search terms included pregnancy, opioid dependency, substance 
misuse/abuse, Subutex, contingency management, and behavioral modification. Since 
Subutex is a relatively new treatment regimen for opioid dependency in pregnancy, little 
research has been conducted to determine the effectiveness of this intervention. To 
overcome this obstacle, the search focused on the use of behavioral modification and 
contingency management to prevent and reduce relapse rates.  
Specific Literature 
Treatment of opioid dependency in pregnant women can be very challenging. 
Practitioners are faced with numerous obstacles, such as relapse and noncompliance in 
following the treatment regimen, and a plethora of medical complications that may occur 
as a result of opioid drug use (Parks et. al., 2012). However, despite these obstacles, 
pregnancy may be a significant opportunity to motivate these women to reduce substance 
use/abuse and implement positive lifestyle changes. Pregnancy can inspire and motivate 
one to adopt positive attitudes that are conducive to positive behavioral changes (Chang 
et. al., 2008). Despite the added stressors, pregnancy is an ideal time to support and 
empower these women to adopt healthy lifestyles (Baffour & Chonody, 2012). Social 
support, knowledge, and strong community programs empower a person  to change 
behavior and overcome oppression.  
The standard of care has shifted from an abstinence-only model to a risk 
reduction, do no harm, encouraging active participation in treatment (Parks et. al., 2012; 
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ACOG, 2012; Wong et. al., 2011). Medication-assisted withdrawal is a popular medical 
intervention to treat opioid dependency, especially in the pregnant population (Jones, 
Finnegan, & Kaltenbach, 2012).Up until recently, the gold standard for treating opioid 
dependency in the pregnant population was the use of methadone as a maintenance 
treatment. However, Subutex has evolved as a feasible treatment option that is deemed 
safe for both the mom and fetus (Wong et.al., 2012). Methadone and Subutex are both 
medications that are used in addiction treatment. Methadone and Subutex are semi 
synthetic long acting opiates that were first discovered in the 1960’s (Wesson & Smith, 
2010). Since the use of Subutex is relatively new, there is not a vast amount of evidence 
available on the safe and effective use in pregnancy.  Researchers at John Hopkins 
conducted a study to compare the effects of methadone and Subutex in pregnancy and in 
the neonatal period (Kakko, Heilig, & Sarman, 2008). Findings from the study suggested 
a decrease in neonatal abstinence scores in the Subutex group; however subjects reported 
a higher rate of dissatisfaction with Subutex therapy (Kakko et. al., 2012).  
General Literature 
In an effort to prevent adverse fetal outcomes, pregnancy is an ideal time to 
motivate women to change negative lifestyle behaviors (Wong et. al., 2011). Harm 
reduction is the goal of  behavioral management therapy (BMT) as the treatment team 
encourages abstinence or a reduction in substance use, treatment of withdrawal 
symptoms, counseling sessions, and pharmacotherapy management (Wong et. al., 2011). 
Contingency management, motivational interviewing, and an educational program to 
counsel women on the risks of drug use in the antepartum, prenatal and postpartum 
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periods are new approaches that may prove to be beneficial in reducing relapse rates in 
opioid dependent pregnant women and enhance one’s desire to change behavior. 
 Contingency management is a behavioral strategy that is based on the use of a 
rewards system to modify behavior (National Collaborating Centre for Mental Health, 
2008). Voucher-based reinforcement, prize-based reinforcement, clinic privileges, and 
monetary incentives are some of the forms of incentives used in contingency 
management (NCCMH, 2008). Due to the limited number of evidence to support the use 
of contingency management in opioid dependent pregnant women, research will need to 
be performed to analyze cost effectiveness and overall effectiveness of this motivational 
strategy in reducing or preventing relapse.     
Motivational interviewing is a goal directed counseling strategy that is used to 
produce behavioral changes in clients (Amodeo et. al., 2011). Individual counseling, 
reflective listening, and helping the client to recognize self-efficacy for change are 
techniques counselors use to produce desired changes in behavior (Amodeo et. al., 2011).  
Interventions focus on identifying factors that increase the potential for opioid and other 
drug use and helping these clients to overcome obstacles and improve life functioning 
and well-being for both themselves and their unborn child (Jones, 2013, p. 90). 
Resistance to treatment may increase if clients feel ashamed, persecuted or branded 
(Parks et. al., 2012). Therefore, it is imperative staff who work with these clients 
maintain a nonjudgmental, supportive attitude. Motivational interviewing is an 
intervention that offers patient-centered counseling in an atmosphere of warmth, 
compassion, and acceptance (Handmaker & Wilbourne, 2001).  
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In order to increase effectiveness of behavioral management therapy (BMT), an 
educational component must be part of the treatment plan.  Education on prenatal care, 
nutrition, the effects of substance use on the fetus, Neonatal Abstienence Scoring (NAS), 
care of the infant after birth, and availability of community resources and support 
services need to be addressed. Programs to support the pregnant client and stabilize the 
home environment after delivery are key to a successful drug free transition (Park et. al., 
2012). 
Conceptual Model and Theoretical Frameworks 
According to Karl Popper (1959), a 20th century social scientist, researchers who 
did not use a theoretical framework as a foundation to guide and collect data are “rank 
empiricists” hoping to find answers through statistical correlation and techniques 
(Kettner, Moroney, & Martin, 2011, p. 32). Using a theoretical framework as a road map 
to guide and direct the project will help in developing and testing hypotheses. This 
project integrates an interpersonal theory to support the process of behavioral change and 
an evidence-based model to develop and test the project question.   
Transtheoretical Model 
Over the past several decades, the transtheoretical model of change (TTM) has 
emerged as one of the most popular models in the field of substance abuse and addiction 
(Velasquez, et. al., 2005). The transtheoretical model is an intrapersonal theory that 
focuses on an individual or a groups’ readiness to change a health behavior (Hodges & 
Videto, 2011). The model is comprised of five stages of readiness that an individual or 
group will transition through in the process of intentional behavioral change: 
19 
 
precontemplation, contemplation, decision/determine, action, and maintenance (Hodges 
& Videto, 2011).  Each stage represents an individual’s level of motivation to change and 
is influenced by intentions, behavior, and attitude (Velasquez et. al., 2005). In the case of 
substance abuse, intentional behavior change is consistent with altering repeated and 
frequent patterns of destructive behavior (Vilela, Jungerman, Laranjeira, & Callaghan, 
2009).  Intentional changing of behavior is essential to the success of substance abuse 
treatment and health promotion programs. Behavior change presents in four dimensions: 
stage, processes, context; and signs of change (Vilela et. al., 2009). Change can be 
measured in both objective and subjective terms as individuals’ cycle through each 
dimension until behavior stability and change is achieved. (Vilela et. al., 2009).  In each 
stage of transition, interventions and strategies can be designed to affect change in 
people, the environment, and behavior. This model can be applied to the process and 
principles of behavioral modification to support and empower behavioral changes.    
The first stage of the model, precontemplation, is defined by denial of the 
undesired behavior as a problem that can lead to destruction and adverse consequences 
(Hodges & Videto, 2011). Often times, if an individual seeks treatment during this phase, 
it is a result of extrinsic external pressures (Vilela et. al., 2009). Psychoeducational 
strategies, such as media campaigns, health appraisals, and individual counseling and 
feedback, can be used successfully to transition individuals to the next stage of the model 
(Hodges & Videto, 2012; Kahl, 2010;Vilela, et.al., 2009).   
In the contemplation stage, there is a recognition that a problem exists and 
intention to change is planned within the next six months (Hodges, & Videto, 2011). 
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Ambivalence to change may be apparent and treatment strategies must focus on the 
positive benefits of behavioral change. Strategies to promote change during this phase 
include motivation and encouragement, behavioral modification, contingency 
management, and self assessment and evaluation to strengthen self efficacy (Kahl, 2010, 
Vilela, 2009).  
Preparation, also known as decisions/determination phase of the model, is 
characterized by a commitment to action. During this stage, strategies should focus on 
developing action plans to strengthen the commitment to behavioral change. Negotiating 
contracts between the client and counselor may be beneficial in reinforcing and 
strengthening commitment (Kahl, 2010). Behavioral modification and group and 
individual counseling sessions help individuals learn goal setting skills as they develop 
individualized action plans that facilitate behavioral change.  
The action stage is marked by modification of past habitual behavioral patterns. 
Clients become active participants in their treatment plan. Interventions that reinforce 
designed action plans are imperative during this stage. Self evaluation, social support 
intervention, and reaffirmation of the commitment to change can be used to promote and 
maintain desired change (Vilela et. al., 2009).  
The maintenance phase is a continuous process where efforts target the 
integration and sustainability of the new behavior. Avoiding relapse is the primary goal 
of treatment and interventions to promote and continually reinforce the new behavior are 
crucial.  Relapse plans must be integral components when designing and developing 
health promotion programs.  
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The TTM defines relapse as an anticipate component of behavioral change where 
a regression in the stages of behavioral change occur (Vilela et. al., 2009). Individuals 
may relapse and cycle back and forth through the various stages of change. During 
relapse, strategies to reinforce the adoption of the new behavior and renewal of self-
confidence will assist in the transition process.  
Transtheoritical model of change  has created a major shift in the treatment and 
care of individuals who exhibit at-risk behaviors (Velasquez et. al., 2005). Behavioral 
modification and contingency management are some of the strategies that can be used to 
motivate individuals to adopt healthy behavior and implement relapse plans. Motivation 
and intentions are key components to fostering active participation in activities to meet 
therapeutic self-care demands (Pickens, 2012). Effective change occurs when clients have 
a desire to change and are active participants in their own self-care.  
Evidenced-Based Models 
In addition, evidence-based practice models (EBP), also known as, models of 
change are designed to aid researchers in the successful transition of new knowledge into 
practice (White & Dudley-Brown, 2012). Effective change is a planned process that 
encompasses the diffusion of new knowledge into the clinical setting. With any change 
process, one must anticipate resistance and plan, control, and manage the effects of the 
planned change on the organization.  An (EBP) model and a change theory or framework 
will help with the systematic integration of new knowledge into the practice environment.  
22 
 
The Stetler Model 
The Stetler Model is an evidence-based practice (EBP) model that reflects a 
practitioner-oriented approach (Stetler, 2001, p. 72).  Originally developed in the 1976, 
and refined in 1994, the Stetler model focuses on research as a systematic process and the 
utilization of research in clinical practice (Stetler, 2001). This model can be applied on an 
organizational level, as well as, an individual level. Nurse can apply the Stetler EBP 
model to improve clinical reasoning and judgment skills. The Stetler EBP model is one of 
the oldest EBP models and has been revised to include EBP outcomes (Gawlinski & 
Rutledge, 2012). The Stetler EBP model integrates both internal and external evidence 
(Stetler, 2001).  Internal evidence is data that is derived from quality assurance data and 
evaluation projects (Gawlinski & Rutledge, 2012). National expert consensus and 
primary research are sources of external evidence that can be used as knowledge to 
support EBP (Gawlinski & Rutledge, 2012).  
The Stetler model is based on a series of critical thinking and decision making 
steps that is supported by the utilization of research and scientific inquiry. The model 
consists of five phases that culminate in evaluating outcomes and goal achievement. The 
first phase of the model is the preparatory phase where researchers determine a purpose 
or problem that is of significance, affirming the existence of the problem through the use 
of internal and external evidence, identifying key stakeholders, and conducting a 
systematic review of literature (Stetler, 2001). In addition, the preparatory phase involves 
developing a project team to assist in the dissemination and implementation of the new 
knowledge into the practice setting.  
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Validation of evidence is the second phase of the model. Critically appraising 
literature for validity and reliability is essential to identifying sufficient evidence that 
supports a need for a change in the practice setting. If there is insufficient evidence to 
support a practice change then the process will terminate in the second phase.  
The third phase, comparative evaluation/decision making, is the synthesis of 
literature to determine if more research will need to be conducted. Patterns or trends in 
data are identified.  Based upon evidence, recommendations are made to accept or reject 
findings (Stetler, 2001).  
The fourth phase, translation/application, is a significant step in the process. This 
phase focuses on the implementation of the new knowledge into practice. Plans are 
developed to facilitate implementation of change on the organizational level. These plans 
should be reflective of evidence-based strategies that foster a climate to embrace new 
knowledge and approaches to practice.  
Evaluations, both formal and informal evaluation, comprise the last phase of the 
Stetler EBP model. Summative and formative evaluations are conducted to measure 
outcome and goal achievement and determine the feasibility of the implemented change 
(Stetler, 2001). In the evaluation phase, researchers will need to calculate cost versus 
benefits of the planned change. Evaluation is an ongoing process that involves 
modification and revision strategies to ensure a successful adaption of change in the 




To summarize major themes in the literature, pregnancy is an opportune time to 
motivate and influence behavioral change and modification. Subutex is a relatively new 
treatment regimen that can be used to treat opioid dependency in the pregnant population. 
However, there is a limited amount of research to prove the safe and effective use of 
Subutex in pregnancy. Research supports the use of behavioral modification interventions 
as an adjunct therapy to motivate behavioral change.  
Literature proves treating opioid dependency in pregnancy can be very 
challenging.  A number of barriers and obstacles can interfere with the success of the 
treatment regimen. However, research suggests pregnancy can be ideal time to influence 
a positive change in positive behavior. This project supports the advancement of nursing 
practice through the use of a healthcare initiative to promote health outcomes for not only 
the new mother bher unborn child. In addition, this project evaluates the effectiveness of 
an existing program in meeting the healthcare needs of a vulnerable population. A 
secondary analysis to determine the effectiveness of behavioral modification in reducing 
relapse rates in the target population will be the preferred approach to conduct the 
project. A descriptive correlational design will be used to examine the relationship 
between variables. The project will be designed using literature to connect and bridge the 
gap in literature to the existing problem. Section 3 will describe in more detail the method 
used in undertaking the project.  
 Conceptual models and theoretical frameworks are significant components in the 
planning and implementation phases to guide and direct the change process. TTM is an 
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interpersonal theory that has been successful in assisting individuals to transition through 
the behavior change process. TTM enables leaders and change agents to design programs 
that are deemed a “good fit” and meets the needs of the target population. In addition, an 
evidence-based model, such as the Stetler model uses evidence to promote and support an 










Section 3: Methodology 
Introduction 
Opioid use in pregnancy can have deleterious outcomes for both the mother and 
unborn child. Interventions to prevent and reduce relapse in opioid dependent clients, 
especially those clients who are pregnant, must be employed. Therefore the purpose of 
this project is to examine the relationship between behavioral modification and relapse in 
opioid dependent pregnant women.  
Section three outlines the project’s approach to designing the project, the methods 
used to design the project, and a description of the population and sampling methods. In 
addition, a description of the data collection methods and data analysis strategies that 
were utilized to answer project questions will be described. Finally, a project evaluation 
plan will be outlined.  
Population and Sampling 
Population-based studies are important in outcome studies as findings reflect the 
total population (Burns & Grove, 2009).  The focus of this secondary analysis was a 
review of medical records to determine if an existing program at the practicum site was 
achieving desired outcomes. To maintain patients’ anonymity and confidentiality of the 
subjects, all medical record numbers and patient information were decoded. The 
accessible population consisted of opioid dependent, pregnant clients over 18 years of 
age, as well as, emancipated minors, who had received Subutex assisted treatment from 
one of three FamilyCare Health Centers located in West Virginia.  
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The sample included all clients from the accessible population who had received 
Subutex assisted treatment from one of the three FamilyCare Health Centers located in 
West Virginia. Inclusion criteria for this analysis were: (a) pregnant female; (b) over 18 
years of age, as well as  emancipated minors; (c) opioid dependent; (d) received treatment 
from the Subutex clinic at one of the three Family Care Clinics in West Virginia. 
Exclusion sampling criteria were: (a) nonpregnant,; (b) under 18 years of age, (c) male, 
(d) clients whose medical records lack required information, (e) clients whose inclusion 
may invoke HIPAA protected information that could be used to identify the patient. 
The Subutex treatment program has been in operation for approximately 2 years. 
Convenience sampling method was used to recruit subjects from three FamilyCare Health 
Centers in West Virginia.  Forty three subjects participated in the DNP project. 
Convenience sampling insured all available subjects who met criteria were included into 
the study.  
Project Design/Methods 
To design a successful project that achieves desired outcomes and project 
objectives, an understanding of the social problem, opioid dependency in pregnancy, is 
essential. This process involves the collection of data periodically throughout the process 
to determine if the program is effectively meeting the needs of the target population 
(Hodges & Videto, 2011). In addition, collecting data from a secondary source, the 
patient’s medical record, will enable project planners to design a program that is deemed 
a good fit for the target group.  Patient identities were protected by assigning a numbering 
system to each patient record.  
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 The purpose of this project was to evaluate an existing program to determine if 
the program is achieving desired outcomes and contingency management and behavioral 
modification are effective in reducing relapse rates in the target population. The program 
has been in effect for several years and during that period of time; no data has been 
collected or analyzed to determine the efficacy of the existing program. The project 
design will focus on analyzing existing data to determine if the program and team is 
promoting compliance of prescribed treatment and minimizing relapse rates in the target 
population.  
 The project method will be an analysis of the collected data to determine if the 
present program at the family care clinics is achieving desired outcomes. Secondary 
analysis design involves analyzing data to determine if the reported findings are meeting 
the needs of the community-based initiative (Burns & Grove, 2009). A retrospective 
secondary analysis utilizing a quantitative approach was conducted which involved 
analyzing data from a target population-opioid dependent pregnant females over the age 
of 18 years who have been participants in the Subutex assisted treatment program at one 
of the three FamilyCare Health Center sites located in south western West Virginia. This 
design methodology was done in a relatively short amount of time as data was easily 
obtained from the medical records. The Gantt chart was used as a timeline to keep the 
project on track.  
Data Collection 
Prior to collecting the data, the approval of Walden University’s Institutional 
Review Board (IRB) was obtained. The role of the IRB is to protect study participants 
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and ensure the project maintains ethical boundaries.  Data was screened to determine if 
participants remained clean without dependency on substances or had fewer than 2 
relapses during the prenatal period. All participants of the project remained anonymous. 
Data were collected using a retrospective chart review.  
The primary source of secondary information was the participants’ medical 
records.  Records were reviewed according to defined criteria. To maintain the principles 
of confidentiality, the author did not have access to the patient’s name or medical record 
number. A coding system was designed to maintain anonymity of health information. No 
identifying information was utilized in the coding of the medical records. Information 
from the medical records with reference to weekly urinalysis results, additional 
medications prescribed during treatment, compliance with counseling, those subjects who 
attended Narcotics Anonymous versus subjects who only attended counseling at the 
family care clinic, and pregnancy related complications were collected. Data were 
screened to determine if participants have remained clean without dependency on 
substances or have had fewer than 2 relapses during their treatment. All participants of 
the project received information regarding the risks and benefits of the project and 
informed consent was obtained prior to data collection. 
Data Analysis 
A secondary analysis of existing data from past participants in the Subutex 
assisted treatment program for opioid dependent pregnant females at the practicum site 
was completed. An analysis of the medical records of past participants enrolled in the 
program over a two year period was undertaken. Data was analyzed using a SPSS 
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software program. The data analysis technique, Analysis of Variance (ANOVA) and 
multiple analysis of variable (MANOVA) were used because of their powerful design 
and capabilities to measure multiple factors (Burns & Grove, 2009). The MANOVA was 
used to measure more than one independent variable (See Appendixes D-H for analysis 
results). 
 The dependent variable was continued abstinence and compliance with the 
treatment regimen with an outcome of a 5% relapse rate. Independent variables included 
age, educational level, socioeconomic level, marital status, history of past pregnancies, 
payer sources, previous treatment for substance abuse, employment, family history of 
drug abuse, exercise, tobacco and alcohol usage, and provision of treatment for legal 
issues.  Outcomes studies focus on analyzing data to determine if a change has occurred 
and in turn use exploratory methods to identify extremes in data, also known as outliers 
(Burns & Grove, 2009). Analysis of change and analysis of improvement are two 
examples of methodology used in outcome studies. Both methods seek to identify 
changes, negative or positive, in the target population through the use of parametric 
statistical analysis to determine significance in their findings (Burns & Grove, 2009). 
Ensuring reliability and validity of outcome measures may be challenging. In outcomes 
studies, data from individuals are used as indicators that correspond to group 
characteristics (Burns & Grove, 2009). To limit threats in reliability, validity, 
consistency, and reduce potential error in the project, a statistician reviewed the SPSS 
spreadsheet for any duplication or errors in recording data.  
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This study used a descriptive, correlational design to examine the relationship 
between behavioral modification and relapse rates. A convenience sample of 43 
individuals who had been enrolled over the previous two years in the Subutex-assisted 
program at the FamilyCare Health Centers were participants in the project. Descriptive 
statistics and regressive analysis were used to analyze data. Data was entered into an 
SPSS program spreadsheet. Variables were entered in column form on the spreadsheet 
and answers were coded using a numerical system. Demographic variables, such as, 
educational level, marital status, unemployment, and a history of depression and anxiety 
explained a significant proportion of the variance in opioid dependence. Subjects who 
participated in counseling, onsite or offsite, displayed less incidences of relapse than 
subjects who did not attend or were not compliant counseling regimen.  
Relapse was measured over different points of time in the Subutex treatment 
program of each subject. Data was analyzed at week 2, week 6, and week 10. 
Project Evaluation Plan 
The evaluation process is an ongoing, continuous process that begins in the early 
phases of program design (Kettner, Moroney, & Martin, 2013). Evaluation is a significant 
component in the planning of effective programs to meet identified needs of the target 
population. Evaluation provides planners with insight into the program’s success, needed 
revisions to improve the efficacy of a program and/or informs decisions regarding future 
community-based initiatives (Hodges & Videto, 2011). Program evaluation must be 
designed to evaluate the effectiveness of a program in meeting goals, objectives and 
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desired outcomes. Several evaluation methods will be utilized in the project to ensure a 
thorough and comprehensive evaluation plan.   
 The logic model is beneficial in developing the evaluation component of a 
program design. The logic model consists of a series of events that link interventions with 
goals, objectives, strategies, and outcomes to determine if the program will be successful 
in producing expected changes in behavior (Komro, Perry, Munson, Stigler, & 
Farbakhsh, 2004). In addition, the logic model incorporates theory into the planning 
process. Highly successful program designs focus on theory, prior research studies, and 
measures to ensure reliability and validity of findings (Komro et. al., 2004).   
 Outcome evaluation is one type of program evaluation strategy to measure 
changes in health or quality of life (Hodges & Videto, 2011). Outcome evaluation 
measures the achievement of long term goals and objectives. In the project, the DNP 
student conducted a secondary analysis of the participants’ medical records to evaluate 
and measure outcomes of the Subutex-assisted program at the practicum site. In 
conclusion, a comprehensive evaluation plan is essential in determining and 
understanding how and why behavioral changes occur and what factors influence those 
changes. A descriptive correlational design utilizing the statistical test, Pearson’s product-
moment correlation coefficient, the measurement of the relationship between behavioral 
modification and an improvement in compliance with the treatment regimen as evidenced 
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Program Logic Model (based on the Social Cognitive Theory) 
Mission Statement: educate, motivate, and support behavioral lifestyle changes in opioid depend pregnant women in an 
effort to produce desired maternal and fetal outcomes and reduce maternal relapse rates. 
Goals:  
To decrease or prevent relapse rates in opioid dependent pregnant females over 18 years of age in 3 counties located in 
rural southwestern West Virginia.  
Promote drug free lifestyle changes in the target population 
Promote positive fetal outcomes in the target population by minimizing or preventing 
prenatal, intrapartum, and postpartum fetal complications or demise.  
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Figure 1.1 Ghant Chart used to diagram the layout for the project 
Summary 
In summary, opioid dependency in the pregnant population can have negative 
consequences for the mother and the unborn child, as well as society. The purpose of this 
project was to evaluate an existing program at three FamilyCare Health Center sites in 
West Virginia to determine if the program was effectively meeting the needs of the target 
population. The project method strived to analyze data from a secondary source to 
determine if the program was promoting positive change in the lives of these women by 
reducing relapse and improving compliance with prescribed treatment.  A report will be 
shared with the organization in the form of a poster presentation at the practicum site. 
Dissemination of findings is essential to the improvement process. The role of 
dissemination is to utilize knowledge in the clinical setting to advance quality healthcare 











Section 4: Findings, Discussion, and Implications 
Introduction 
The purpose of this project was to evaluate the effectiveness of behavioral 
modification therapy in reducing relapse rates in opioid dependent pregnant women who 
were enrolled in a Subutex-assisted treatment program offered at a FamilyCare Health 
Center in West Virginia The project question focused on the relationship between 
behavioral modification in combination with Subutex-assisted therapy to reduce relapse 
rates in opioid dependent pregnant women over the age of 18 years as well as 
emancipated minors. To answer this question, a secondary analysis using a retrospective 
design was preformed.  
Summary of Findings 
In review, this project had three clear objectives: (a) a secondary analysis of 
data(b) evaluate the effectiveness of behavioral modification therapy in minimizing 
relapse rates in opioid dependent pregnant females over the age of 18 years of age (as 
well as emancipated minors) who have been enrolled in a Subutex-assisted treatment 
program (c) report the results of the analysis to the team at the clinic. Each objective was 
achieved. A secondary analysis of the data was completed and the analysis supported the 
assumption that behavioral modification interventions are effective in reducing relapse in 
opioid dependent pregnant women. Finally, the results of the project were reported to the 
team at the FamilyCare Health Centers..  
The project question asked: What is the relationship between behavioral 
modification in combination with Subutex-assisted therapy and relapse rates in opioid 
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dependent pregnant women over the age of 18 years as well as emancipated minors? In 
the study, there were no significant findings to support a relationship between counseling 
and relapse. Therefore, counseling using behavioral modification strategies in 
combination with Subutex was not supported to reduce relapse rates and motivate opioid 
dependent pregnant women to avoid illicit drug usage.  
PICO: In pregnant opioid dependent women  over 18 years of age does behavioral 
modification drug abuse counseling in combination with Subutex-assisted therapy, 
compared to no drug abuse counseling, reduce relapse rates by more than 5% in the 
prenatal period?   
In evaluation, behavioral modification and counseling in conjunction with Subutex-
assisted therapy compared with Subutex assisted therapy and non compliance with 
clinical contract mandating counseling sessions utilizing behavioral modification 
interventions may or may not have the potential to reduce or prevent relapse in opioid 
dependent pregnant females. However, in the study, relapse rates were slightly higher 
than the proposed 5%.  
Literature stresses a number of factors can influence relapse rates (Jones, 2013; 
Parks et. al., 2011; Tkacz et. al., 2012). In the study, a number of intrapersonal and 
environmental factors contributed to relapse. The majority of relapse incidences were due 
to inability of the participant to manage stress and conflict. In addition, living in an 
environment where drug abuse is prevalent led to relapse.   
In summary, the study results supported the review of literature stating on the 
behavioral modification when used with Subutex-assisted therapy can reduce relapse 
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rates in the target population.  Despite the slightly higher incidence of relapse obtained 
from the study results, relapse can be minimized when patients are compliant with 
counseling that advocate behavioral modification strategies.  In addition, the study 
concluded health outcomes of both the expectant mother and the unborn child were 
improved. A very low percentage of the sample population experienced adverse prenatal 
outcomes such as miscarriages, abruptio placenta, and premature labor.      
Literature Discussion 
The literature showed that behavioral modification therapy in conjunction with a 
structured medical treatment plan can produce positive heath outcomes in pregnant 
women who have opioid dependency. In the project study, the target population exhibited 
confounding factors, such as hepatitis, sexually transmitted diseases, poor socioeconomic 
status, unemployment, depression, past history of abuse, and other factors that 
contributed to negative lifestyles leading to drug dependence and misuse. This is 
consistent with studies conducted by Wong et. al. (2011) and Anderson, Roux, and Pruitt 
(2002), which stated confounding factors associated with substance abuse can contribute 
to poor maternal and fetal outcomes.  
Consistent with findings from studies conducted by Parks et. al. (2012) and Pinto 
et. al. (2010), serious medical complications, such as abruptio placenta, spontaneous 
abortions, and preterm labor to mention a few can be a direct reflection of opioid use in 
pregnancy. The project study confirmed that opioid use and dependency during 
pregnancy can lead to serious medical complications as several subjects experienced 
adverse effects, such as preterm labor, abruptio placenta, and spontaneous abortions. 
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These results support the need for behavioral modification as a means to promote healthy 
lifestyle changes that lead to improved maternal and fetal outcomes.  
Due to high relapse rates in the opioid dependent population, opioid dependence 
is known as a chronic relapsing disorder (Tkacz et. al., 2012). Studies prove that relapse 
is associated with a number of intrapersonal and environmental factors that can 
exacerbate drug misuse and abuse (Jones, 2013;Parks et. al., 2011; Tkacz et. al., 2012). 
Parallel to the project findings, factors such depression and inability to manage stress, as 
well as, a partner who has problems with drug dependence can contribute to relapse. 
Behavioral modification and counseling are health interventions to promote a lifestyle 
change that is reflective of best practice and treatment regimens individualized to meet 
the needs of the patient. Pregnancy is an ideal time to motivate expecting mothers to 
transition to a drug free lifestyle.  
Implications 
Policy 
Over the last decade, death from drug misuse and abuse has increased twofold 
(Schreiner, 2012). Policy makers have an obligation to advocate for policies that regulate 
and monitor drug prescribing and illegal issuing of substances. Prescription Drug 
Monitoring Programs (PDMP) is an effective strategy to assist physicians in identifying 
prescription drug misuse and prevent potential indiscriminate drug prescribing 
(Schreiner, 2012). Designing effective programs to combat the present drug abuse 
epidemic is one solution to winning the war against drugs. 
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This capstone project can influence policy makers to consider continued funding for 
social programs that are designed to prevent and control drug misuse and abuse. Using 
interventions, such as behavioral modification techniques, in conjunction with medication 
can produce positive health outcomes. In addition, this project can have implications for 
future laws and regulations that govern the treatment of vulnerable populations, such as 
pregnant women.  
The court system has the power to transform healthcare by imposing legal statutes 
on the medical profession. Changing and implementing new policies and regulations will 
be a giant step in preventing drug misuse and abuse. If proven successful, community 
based programs, such as the Subutex- assisted treatment program for opioid dependent 
pregnant women, can meet accountability benchmarks and receive further support and 
needed funding. 
Practice 
Bringing evidence into the clinical setting can transform practice. Throughout the 
decades, nursing practice has been based on rituals and traditions that have used as a 
guide to decision making in the practice setting (Brown et. al., 2010). However, when 
research is integrated into the practice setting, evidence supports patient outcomes 
improve and clinical judgment and decision making skills are perfected. This project 
supports the premise that health interventions when used in conjunction with a medical 
treatment regimen can produce health outcomes that have wide spread effects.  It is the 
responsibility of every nurse to share their knowledge with other members of the 
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healthcare community. Disseminating the project results with healthcare professionals 
will develop knowledge that can affect care provision in the practice setting.  
Healthcare professionals must collaboratively work together to design community 
based programs that target diverse populations. In the planning process, program planners 
must integrate ongoing strategies for performance measurement, monitoring, and 
evaluation (Kettner et. al., 2013). In hindsight, the practicum site did not integrate 
ongoing measures to monitor the performance and success of the Subutex-assisted 
program for the target population. Therefore, the clinical site could not surmise the 
implications and output of their program. In assessment, it must be stressed program 
planners use a variety of strategies are in place to ensure ongoing monitoring of 
programs. Monitoring for performance effectiveness, quality, cost effectiveness and 
efficiency are strategies that can be useful to secure funding and resources to improve 
existing programs or design new quality initiatives.  
Research 
Bringing research into the practice setting can transform healthcare. Implementing 
interventions that are supported by evidence can produce favorable outcomes for 
stakeholders.  This project supports research utilization as a best practice measure and 
should be used in the decision making process to decide what is the best treatment option 
for the patient. Utilizing interventions and life’s circumstances such as pregnancy, can 
positively affect behavioral changes that are lifelong and sustainable.  
Further research studies are needed to determine the efficacy of behavioral 
modification in reducing relapse rates in opioid dependent pregnant women. Due to the 
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small cohort size, generalizations cannot be conclusively inferred from the results of the 
project. Additional research studies will need to be conducted on behavioral modification 
interventions to determine if treatment engagement and participation, as well as, outcome 
performance measurement is improved.  
Social Change 
Community based programs are designed to overcome social problems that are 
threatening social values and meet the needs of the targeted population (Kettner et. al., 
2013). In order to enact positive social change, programs must educate program 
participants on the importance of behavioral change strategies that lead to a healthy 
lifestyle change (Kettner et. al., 2013). This project evaluates the efficacy of a health 
intervention to produce a healthy outcome for not only a pregnant female but her unborn 
child also. Through understanding of behavioral change strategies and implementing 
behavioral change models, such as the transtheoretical model of behavior change, 
positive behavioral change can occur. Healthcare disparities can be overcome and best 
practices can be employed. In order for social based programs to be successful, needs of 
the target population must be met and participants must be motivated to change their 
behavior 
Project Strengths and Limitations  
Strengths 
The findings of this study were consistent with previous studies conducted on  
drug addiction and behavioral modification ( Parks et. al., 2012; Jones, 2013; Tkacz et. 
al., 2012). The findings of this study support growing evidence promoting behavioral 
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modification as an effective intervention that motivates one to change their lifestyle. 
Synthetic opioids, such as Subutex, when used alone, may not be sufficient to prevent or 
minimize relapse in opioid dependency. Therefore, behavioral modification when used in 
combination with Subutex-assisted therapy can have a positive influence on the 
prevention and reduction of relapse in opioid dependency.  
In addition, the application of diverse theories (TTM, and the Stetler model) laid 
the foundation upon which to construct the project.  The transtheoretical model of change 
is an excellent intrapersonal theory that explains the process of behavioral change and 
can be used to assess one’s readiness to change. In addition, the Stetler model provides a 
framework for the translation of evidence into practice. In order for change to be 
sustainable, the application of theories/models provides a solid foundation for change to 
occur. Future recommendations for future projects or research include focusing on health 
outcomes of the infant born to an opioid dependent mother and interventions to prevent 
relapse in addicted clients.  
Limitations 
 One limitation of this project was the small size of the sample population. 
Initially, the sample size was thought to be between 60 – 100 participants. However, not 
all the participants’ medical records could be found. Therefore, study findings may not be 
generalized to the larger population representing opioid dependent pregnant women.  
 Another limitation of the study was methodological. A limited amount of 
information related to variables could be found in the medical record. In some instances, 
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there was very little documentation or missing documentation on identified variables, 
making accuracy of data collection and analysis difficult.  
Analysis of Self 
The DNP capstone project is an integrative clinical practice encounter that  
culminates into a learning experience that is designed to promote a student’s professional 
and personal growth. This learning experience prepares a student to assume leadership 
qualities that promote professional growth not only as a scholarly practitioner but as a 
practitioner that is committed to clinical scholarship and advancing clinical practice and 
improving health outcomes. Throughout this academic journey, the student has grown 
both personally and professionally and is prepared to assume the aggregate role of a DNP 
practitioner. Self refection is a way to evaluate personal and professional growth.  
As Scholar 
 An essential component of advancement in professional development is 
the application of scholarly activity. Scholarly activity promotes the sharing of evidence 
to support advancements in clinical practice and quality improvement initiatives and 
interventions to improve healthcare outcomes (Thomas, Karr, Kelley, & McBane, 2012). 
Scholarly activity fosters an environment that promotes the application of research to 
design changes in practice to support a new way of thinking or to create an awareness of 
clinical outcomes or produce a scholarly product ( Zaccagnini & White, 2011).  
According to the American Nurses Association (ANA) Code of Ethics for Nurses 
Provision 5:2 Professional Growth and Maintenance of Competence, it is every nurse’s 
professional responsibility to be a self directed learner and commit one’s self to lifelong 
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learning (ANA, 2010). Reflecting back on practicum experiences throughout courses 
NURS 8400, NURS 8410, and NURS 8500, the author has developed a number of skills 
and attributes to promote leadership and collaborative relationships. This commitment to 
lifelong learning has assisted the author in the acquisition of knowledge that is in line 
with current standards and scope of nursing practice to network with professional 
colleagues, confront changing practice issues that produce positive health and patient 
outcomes. In return, the author has the knowledge and skill to transform evidence into 
clinical practice to support needed changes in today’s’ healthcare arena and improve the 
future of the nursing profession.  
As Practitioner 
The practitioner plays a significant role in bringing evidence to the bedside to 
transform and support changes in clinical practice. The DNP practicum experience guides 
the advanced practice nurse to understand the link between nursing theory, research, and 
clinical practice (Terry, 2012). According to Terry (2012), “nursing theory guides nursing 
practice, it is practice that tends to generate the questions that will ultimately form 
research questions or hypotheses, and it is research that will aid in the development of 
guidelines for practice” (pg. 28).  
To transform the future of healthcare, the nurse realizes the importance of 
utilizing all available resources. In addition, the advanced practice nurse performs as a 
skilled practitioner with specialized knowledge to treat patients, their families, and the 
community using a holistic approach. In this manner, the advance practice nurse can 
identify changing practice trends and integrate those trends into clinical practice, link 
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systematic level changes into the healthcare arena, and promote positive health outcomes 
by educating patients in self care and management of chronic disease and foster healthy 
lifestyle changes and decision making skills that lead to positive outcomes (Terry, 2012). 
The author has grown as a skilled practitioner who uses knowledge and leadership 
skills to bring evidence into the clinical setting. This knowledge and skill can be used to 
guide practice changes, promote cost-effective healthcare, and reform the present day 
healthcare system. Quality healthcare is the paradigm of the future of healthcare and the 
nursing profession.  
As Project Developer 
In today’s healthcare arena, quality care, cost-effectiveness, and performance 
accountability are of the utmost importance. Federal agencies and regulatory bodies 
scrutinize practices of healthcare institutions and programs reducing funding and cutting 
human service programs if performance is deemed below average. Therefore, it is 
essential healthcare services design programs that meet the mandated performance 
requirements of payer and funding sources and evaluate if the needs of the target 
population are being met (Kettner, Moroney, & Martin, 2013).  
The activities of the practicum experience form a basis upon which continual 
improvement of healthcare services and programs evolve and decision making processes 
to improve and make changes in existing and new healthcare programs are utilized 
(Kettner  et. al., 2013). During the DNP practicum, the author has developed skills and 
knowledge to assess the needs of a target population, design programs to meet those 
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needs, measure performance accountability, and evaluate the effectiveness and efficiency 
of quality improvement initiatives. 
As a DNP prepared nurse, the author has the ability and determination to be a 
transformational leader and create effectiveness-based planning systems that focus on 
performance improvement, performance measurement, and program evaluation. In 
addition, the author can lead the way for future healthcare reform through the transition 
of evidence into clinical practice.  
Future Professional Development 
The American Associated Colleges of Nursing (AACN) Essentials of Doctoral 
Education, defines advanced practice nursing as “any form of nursing intervention that 
influences healthcare outcomes for individuals or populations” (AACN, 2006, p. 4). To 
overcome disparities in healthcare, healthcare professionals must address social problems 
and design interventions that focus on client need (Kettner, et. al., 2013). Program 
planners must design programs focusing on interventions, such as behavioral 
management, that assist clients in achieving desired goals, objectives, and positive 
outcomes.   
The future of healthcare depends on leaders who can apply effectiveness 
principles to define social problems, collaborate with others to design interventions and 
programs that target the needs of diverse populations, and evaluate the success or failure 
of the quality improvement initiative. Determining the relationship between variables will 
assist program planners to understand future trends in planning programs that are 
effective and cost efficient. Finally, professional development grows when one learns 
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from the experiences of others. Taking into consideration past successes and failures of 
existing programs, collecting and analyzing data, developing an awareness of financial 
and regulatory issues, and integrating feedback from others will lead to reformation of 
healthcare programs that promote continuum of care to achieve desired results.  
Summary 
This secondary analysis was performed to evaluate the effectiveness of an 
intervention and a program to produce positive health outcomes for opioid dependent 
pregnant women. Specifically, behavioral modification therapy was evaluated to 
determine if the program was successful in reducing relapse rates in opioid dependent 
pregnant females. Drug abuse and misuse has increased globally and is creating a public 
health crisis that is having devastating effects on society. Community based programs 
utilizing interventions that promote healthy lifestyle change must be designed in such a 
way to meet the needs of the target population. This project stresses the importance of 








 Section 5: Scholarly Product and Evaluation 
Project Summary 
This project was designed based upon the results of a needs assessment. The 
misuse of drugs and the rising incidence of opioid dependence and misuse in West 
Virginia and the United States have creating a public health crisis. Discussing the issue 
with community healthcare leaders, it was brought to the attention of the author, a 
secondary analysis of a community based intervention, behavioral management, was 
needed to determine if the goals and objectives of one community based program was 
meeting the needs of a target population and producing positive health outcomes. 
Therefore, with cooperation of the FamilyCare Health Center  t he project was initiated. 
After touring the FamilyCare Health Center and discussing the community based 
program with members of the staff, the project was designed to determine if behavioral 
management therapy, along with Subutex, could reduce relapse rates in pregnant opioid 
dependent pregnant females. A secondary analysis of the health intervention was 
determined to be the most efficacious method of evaluation. The clinic gathered medical 
records of program participants over the last several years and, in an effort to maintain 
confidentiality, designed an anonymous patient medical record numbering system. To 
further ensure confidentiality and protection of patient privacy, the medical records were 
housed in a locked file cabinet in an office at one of the clinical sites. Only the chief 
nursing officer was allowed access to the records. Through the use of a SPSS software 
program, data were recorded and analyzed. Measures were put into place to monitor for 
accuracy of data entry.  
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Project Evaluation Report 
 Program evaluation is defined as “social science techniques applied to 
determining the workings and effectiveness of social programs” (Kettner, Moroney, & 
Martin, 2013, p. 231). Healthcare organizations utilize program evaluations to determine 
the value and impact of an intervention and its effects in producing positive health 
outcomes. Impact program evaluation strives to identify cause and affect relationships 
and determine if the program is meeting the needs of the target group (Kettner et. al., 
2013). In addition, feedback from the evaluation can be used to inform policy makers 
about intended versus unintended benefits and/or consequences of the intervention to 
evoke changes or redesign social policies or programs (Kettner et. al., 2013).  
Program evaluation uses outcome measurement to improve existing programs and 
plan for new initiatives. Program evaluation integrates both formative and summative 
evaluation principles to complete a program assessment. Once data is collected and 
assessed, recommendations are reported to social service-funding agencies in an effort to 
secure needed revenue to continue support of community programs. Evaluating the 
effectiveness and necessity of programs will help to resolve the current healthcare crisis 
in the United States by eliminating funding for unnecessary programs that are not 
effectively meeting the needs of the population group.  
In evaluating the project, a number of factors were analyzed. The project was a 
determined to be of significant importance to not only the community but to overall 
health outcomes of this vulnerable population- opioid dependent pregnant female. 
Confidentiality and anonymity of subjects was maintained throughout this project. 
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Identified variables were determined to be relevant to the project. SPSS software 
analyzed the collected data and measures were implemented to ensure accuracy of 
results. Two reviewers assessed data that was entered into the program for accuracy. 
However, one limitation of this project was in relation to the size of the sample 
population. Future projects will need to increase the sample size thereby improving 
generalization of results. In conclusion, evaluation findings and recommendations will be 
disseminated to the FamilyCare Health Center staff at a future poster presentation 
planned at site. This feedback can be used to maintain sustainability of the existing 
program and healthcare intervention or make changes to improve future programs and 
quality initiatives.  In addition, the importance of ongoing evaluation, continually 
monitoring program processes, measures, and results/improvements, will be stressed to 
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Table 1A.  
Case Processing Summary of the *UDS Other-  













Gender *UDS other     38             88.4%          5                11.6%          43           100% 




    38             88.4%          5                11.6%           43          100% 
Age *UDS other     38             88.4%          5                11.6%           43          100% 
Marital Status * UDS 
other 
    38             88.4%          5                11.6%           43          100% 
Education Level 
*UDS other 
    36             83.7%          7                16.3%           43          100% 
Employed *UDS 
other 
    38             88.4%          5                11.6%           43          100% 
*Previous Treatment 
*UDS other 





    38             88.4%          5                11.6%           43          100% 
Family History of 
Drug 
Abuse* UDS other 
    31             72.1%          12               27.9%          43          100% 
Exercise * UDS other     38             88.4%          5                 11.6%          43          100% 
Tobacco User *UDS 
other 
    38             88.4%          5                 11.6%          43          100% 
Alcohol User *UDS 
other 
    36             83.7%          7                 16.3%          43          100% 







Table 1B.  
 
Case Processing Summary of the *UDS Cannabis 











Gender *UDS cann     38             88.4%          5                11.6%          43           100% 




    38             88.4%          5                11.6%           43          100% 
Age *UDS cann     38             88.4%          5                11.6%           43          100% 
Marital Status * UDS 
cann 
    38             88.4%          5                11.6%           43          100% 
Education Level 
*UDS cann 
    36             83.7%          7                16.3%           43          100% 
Employed *UDScann     38             88.4%          5                11.6%           43          100% 
*Previous Treatment 
*UDS cann 





    38             88.4%          5                11.6%           43          100% 
Family History of 
Drug Abuse* 
UDS cann 
    31             72.1%          12               27.9%          43          100% 
Exercise * UDS cann     38             88.4%          5                 11.6%          43          100% 
Tobacco User *UDS 
cann 
    38             88.4%          5                 11.6%          43          100% 
Alcohol User *UDS 
cann 
    36             83.7%          7                 16.3%          43          100% 
 
 





Table 1C.  
 
Case Processing Summary of the *UDS THC 











Gender *UDS THC     38             88.4%          5                11.6%          43           100% 




    38             88.4%          5                11.6%           43          100% 
Age *UDS THC     38             88.4%          5                11.6%           43          100% 
Marital Status * UDS 
THC 
    38             88.4%          5                11.6%           43          100% 
Education Level 
*UDS THC 
    36             83.7%          7                16.3%           43          100% 
Employed *UDS 
THC 
    38             88.4%          5                11.6%           43          100% 
*Previous Treatment 
*UDS THC 





    38             88.4%          5                11.6%           43          100% 
Family History of 
Drug Abuse* 
UDS THC 
    31             72.1%          12               27.9%          43          100% 
Exercise * UDS THC     38             88.4%          5                 11.6%          43          100% 
Tobacco User *UDS 
THC 
    38             88.4%          5                 11.6%          43          100% 
Alcohol User *UDS 
THC 
    36             83.7%          7                 16.3%          43          100% 
 
 







Case Processing Summary of the *UDS Oxycodone-  











Gender *UDS oxyc     38             88.4%          5                11.6%          43           100% 




    38             88.4%          5                11.6%           43          100% 
Age *UDS oxyc     38             88.4%          5                11.6%           43          100% 
Marital Status * UDS 
oxyc 
    38             88.4%          5                11.6%           43          100% 
Education Level 
*UDS oxyc 
    36             83.7%          7                16.3%           43          100% 
Employed *UDS 
oxyc 
    38             88.4%          5                11.6%           43          100% 
*Previous Treatment 
*UDS oxyc 





    38             88.4%          5                11.6%           43          100% 
Family History of 
Drug Abuse* 
UDS oxyc 
    31             72.1%          12               27.9%          43          100% 
Exercise * UDS oxyc     38             88.4%          5                 11.6%          43          100% 
Tobacco User *UDS 
oxyc 
    38             88.4%          5                 11.6%          43          100% 
Alcohol User *UDS 
oxyc 
    36             83.7%          7                 16.3%          43          100% 
 
 







Case Processing Summary of the *UDS Amphetamine 











Gender *UDS amph     38             88.4%          5                11.6%          43           100% 




    38             88.4%          5                11.6%           43          100% 
Age *UDS amph     38             88.4%          5                11.6%           43          100% 
Marital Status * UDS 
amph 
    38             88.4%          5                11.6%           43          100% 
Education Level 
*UDS amph 
    36             83.7%          7                16.3%           43          100% 
Employed *UDS 
amph 
    38             88.4%          5                11.6%           43          100% 
*Previous Treatment 
*UDS amph 





    38             88.4%          5                11.6%           43          100% 
Family History of 
Drug Abuse* 
UDS amph 
    31             72.1%          12               27.9%          43          100% 
Exercise * UDS 
amph 
    38             88.4%          5                 11.6%          43          100% 
Tobacco User *UDS 
amph 
    38             88.4%          5                 11.6%          43          100% 
Alcohol User *UDS 
amph 





















































Case Processing Summary of the *UDS Benzodiazipine  











Gender *UDS benzo     38             88.4%          5                11.6%          43           100% 




    38             88.4%          5                11.6%           43          100% 
Age *UDS benzo     38             88.4%          5                11.6%           43          100% 
Marital Status * UDS 
benzo 
    38             88.4%          5                11.6%           43          100% 
Education Level 
*UDS benzo 
    36             83.7%          7                16.3%           43          100% 
Employed *UDS 
benzo 
    38             88.4%          5                11.6%           43          100% 
*Previous Treatment 
*UDS benzo 





    38             88.4%          5                11.6%           43          100% 
Family History of 
Drug Abuse* 
UDS benzo 
    31             72.1%          12               27.9%          43          100% 
Exercise * UDS 
benzo 
    38             88.4%          5                 11.6%          43          100% 
Tobacco User *UDS 
benzo 
    38             88.4%          5                 11.6%          43          100% 
Alcohol User *UDS 
benzo 
    36             83.7%          7                 16.3%          43          100% 
 







Report of UDS Other (2nd week) and Variables 






































































































































































































Table 2A (continued) 
 
Report of UDS Other  (2nd week)  and Variables 
























































































Table 2B.  
 
Report of  UDS Cannabis and Variables (Week 2) 
UDS THC Sex Payer
r





























































































































































































Table 2B(continued)  
 
Report of UDS Cannabis and Variables (Week 2) 


















































































Table 2C   
 
Lowest incidence of  drug misused- week 6  (n=43) 
 
) 
UDS  Sex Payer Pov L Age Marital 
 




















































































































































































Report of UDS Amphe and Variables (Week 2) (continued) 

























































































Table 3A  
 
ANOVA Results UDS Other (Week 2) 
Variables F Sig. 
Payer *UDS other                                     Between Groups 
(combined) 
                                                                   Within Groups 
                                                                   Total 
.947 .337 
Poverty Level Percentage                          Between Groups 
(combined*UDS other                               Within Groups 
                                                                   Total      
.513 .478 
Age *UDS other                                        Between Groups 
(combined) 
                                                                   Within Groups 
                                                                   Total 
.080 .779 
Marital Status *UDS other                        Between Groups 
(combined) 
                                                                   Within Groups 
                                                                   Total 
.051 .823 
Education Level                                         Between Groups 
(combined) 
 *UDS other                                               Within Groups 
                                                                   Total 
.306 .584 
Employed *UDS other                              Between Groups 
(combined) 
                                                                   Within Groups 
                                                                   Total 
.637 .430 
Previous Treatment                                    Between Groups 
(combined) 
*UDS other                                                Within Groups 
                                                                   Total 
1.540 .223 
Treatment Prov                                          Between Groups 
(combined) 
*UDS other                                                Within Groups 
                                                                   Total 
1.071 .308 
Family History                                           Between Groups 
(combined) 
*UDS other                                                Within Groups 
                                                                   Total 
1.998 .168 
Exercise                                                     Between Groups 
(combined) 
*UDS other                                                Within Groups 




Tobacco User                                             Between Groups 
(combined) 
*UDS other                                                Within Groups 
                                                                   Total 
.513 .478 
Alcohol User                                             Between Groups 
(combined) 
*UDS other                                                Within Groups 
                                                                   Total 
.540 .468 







































Table 3B  
 
ANOVA Results UDS Cannabis (Week 2) 
Variables F Sig. 
Payer *UDS Cann                                     Between Groups 
(combined) 
                                                                   Within Groups 
                                                                   Total 
.185 .670 
Poverty Level Percentage                          Between Groups 
(combined) *UDS Cann                                               Within 
Groups 
                                                                   Total      
.305 .584 
Age *UDS Cann                                        Between Groups 
(combined) 
                                                                   Within Groups 
                                                                   Total 
.3.045 .089 
Marital Status *UDS Cann                        Between Groups 
(combined) 
                                                                   Within Groups 
                                                                   Total 
.372 .546 
Education Level                                         Between Groups 
(combined) 
 *UDS Cann                                               Within Groups 
                                                                   Total 
.844 .365 
Employed *UDS Cann                              Between Groups 
(combined) 
                                                                   Within Groups 
                                                                   Total 
2.305 .138 
Previous Treatment                                    Between Groups 
(combined) 
*UDS Cann                                                Within Groups 
                                                                   Total 
.597 .445 
Treatment Prov                                          Between Groups 
(combined) 
*UDS Cann                                                Within Groups 
                                                                   Total 
.783 .382 
Family History                                           Between Groups 
(combined) 
*UDS Cann                                                Within Groups 
                                                                   Total 
.104 .749 
Exercise                                                     Between Groups 
(combined) 




                                                                   Total 
Tobacco User                                             Between Groups 
(combined) 
*UDS Cann                                                Within Groups 
                                                                   Total 
.305 .584 
Alcohol User                                             Between Groups 
(combined) 
*UDS Cann                                               Within Groups 
                                                                   Total 
.084 .774 






































Table 3C  
 
ANOVA Results UDS Amphetamines (Week 2) 
Variables F Sig. 
Payer *UDS Amph                                    Between Groups 
(combined) 
                                                                   Within Groups 
                                                                   Total 
.183 .671 
Poverty Level Percentage                          Between Groups 
(combined) *UDS other Amph                                    Within 
Groups 
                                                                   Total      
.026 .872 
Age *UDS Amphe                                     Between Groups 
(combined) 
                                                                   Within Groups 
                                                                   Total 
.260 .613 
Marital Status *UDS Amph                      Between Groups 
(combined) 
                                                                   Within Groups 
                                                                   Total 
.263 .611 
Education Level                                         Between Groups 
(combined) 
 *UDS Amph                                             Within Groups 
                                                                   Total 
.376 .544 
Employed *UDS Amph                             Between Groups 
(combined) 
                                                                   Within Groups 
                                                                   Total 
.455 .504 
Previous Treatment                                    Between Groups 
(combined) 
*UDS Amph                                              Within Groups 
                                                                   Total 
.805 .375 
Treatment Prov                                          Between Groups 
(combined) 
*UDS Amph                                             Within Groups 
                                                                   Total 
.054 .817 
Family History                                           Between Groups 
(combined) 
*UDS Amph                                              Within Groups 
                                                                   Total 
.935 .341 
Exercise                                                     Between Groups 
(combined) 




                                                                   Total 
Tobacco User                                             Between Groups 
(combined) 
*UDS Amph                                               Within Groups 
                                                                   Total 
.026 .872 
Alcohol User                                             Between Groups 
(combined) 
*UDS Amph                                               Within Groups 
                                                                   Total 
2.061 .160 






































Table 4A  
 
Case Processing Summary of the *UDS Cannabis 











Gender *UDS Cann     29             67.4%          14               32.6%          43           
100% 
Payer *UDS Cann     29             67.4%          14              32.6%           43           
100% 
Poverty Level * Cann     29             67.4%          14               32.6%           43          
100% 
Age *UDS Cann     29             67.4%          14                32.6%          43          
100% 












    29             67.4%          14                32.6%           43          
100% 




Family History of 
Drug Abuse 
    24             55.8%          19                44.2%          43          
100% 
Exercise * UDS Cann     29             67.4%          14                32.6%          43           
100% 
Tobacco User*UDS     29             67.4%          14                 32.6%          43          
100% 
Alcohol User *UDS      27             62.8%          16                 37.2%          43          
100% 
 






























Case Processing Summary of the *UDS THC-  











Gender *UDS THC     29             67.4%          14               32.6%          43           
100% 





    29             67.4%          14               32.6%           43          
100% 
Age *UDS THC     29             67.4%          14                32.6%          43          
100% 
Marital Status * UDS 
THC 


















    29             67.4%          14                32.6%           43          
100% 
Family History of 
Drug 
    24             55.8%          19                44.2%          43           
100% 
Exercise * UDS THC     29             67.4%          14                32.6%          43           
100% 
Tobacco    
                                    
   
  
 




















































Case Processing Summary of the *UDS Benzodiazipine 











Gender *UDS Benzo     22             51.2%          21                48.8%          43           
100% 





    22             51.2%          21                48.8%           43          
100% 
Age *UDS Benzo     22             51.2%          21                48.8%           43          
100% 
Marital Status * UDS 
Benzo 


















    22             51.2%          21                48.8%           43          
100% 
Family History of 
Drug Abuse* 
UDS Benzo 
    18             49.1%          25                 58.1%          43          
100% 
Exercise * UDS 
Benzo 
    22             51.2%          21                 48.8%          43          
100% 
Tobacco User *UDS 
Benzo 
    22             51.2%          21                 48.8%          43          
100% 
Alcohol User *UDS 
Benzo 











ANOVA Results UDS Cannabis (week 6) 
Variables F Sig. 
Payer *UDS Cann                                     Between Groups 
(combined) 
                                                                   Within Groups 
                                                                   Total 
.002 .968 
Poverty Level Percentage                          Between Groups 
(combined) *UDS Cann                                               Within 
Groups 
                                                                   Total      
.254 .618 
Age *UDS Cann                                        Between Groups 
(combined) 
                                                                   Within Groups 
                                                                   Total 
.000 .997 
Marital Status *UDS Cann                        Between Groups 
(combined) 
                                                                   Within Groups 
                                                                   Total 
.316 .579 
Education Level                                         Between Groups 
(combined) 
 *UDS Cann                                               Within Groups 
                                                                   Total 
.202 .657 
Employed *UDS Cann                              Between Groups 
(combined) 
                                                                   Within Groups 
                                                                   Total 
.017 .896 
Previous Treatment                                    Between Groups 
(combined) 
*UDS Cann                                                Within Groups 
                                                                   Total 
.772 .387 
Treatment Prov                                          Between Groups 
(combined) 
*UDS Cann                                                Within Groups 
                                                                   Total 
1.089 .306 
Family History                                           Between Groups 
(combined) 
*UDS Cann                                                Within Groups 
                                                                   Total 
.090 .767 
Exercise                                                     Between Groups 
(combined) 




                                                                   Total 
Tobacco User                                             Between Groups 
(combined) 
*UDS Cann                                                Within Groups 
                                                                   Total 
.254 .618 
Alcohol User                                             Between Groups 
(combined) 
*UDS Cann                                               Within Groups 
                                                                   Total 
.021 .885 







































Table 5B  
 
ANOVA Results UDS THC (week 6) 
Variables F Sig. 
Payer *UDS THC                                     Between Groups 
(combined) 
                                                                   Within Groups 
                                                                   Total 
.002 .968 
Poverty Level Percentage                          Between Groups 
(combined) *UDS THC                                               Within 
Groups 
                                                                   Total      
.254 .618 
Age *UDS THC                                        Between Groups 
(combined) 
                                                                   Within Groups 
                                                                   Total 
.000 .997 
Marital Status *UDS THC                        Between Groups 
(combined) 
                                                                   Within Groups 
                                                                   Total 
.316 .579 
Education Level                                         Between Groups 
(combined) 
 *UDS THC                                               Within Groups 
                                                                   Total 
.202 .657 
Employed *UDS THC                              Between Groups 
(combined) 
                                                                   Within Groups 
                                                                   Total 
.017 .896 
Previous Treatment                                    Between Groups 
(combined) 
*UDS THC                                                Within Groups 
                                                                   Total 
.772 .387 
Treatment Prov                                          Between Groups 
(combined) 
*UDS THC                                                Within Groups 
                                                                   Total 
1.089 .306 
Family History                                           Between Groups 
(combined) 
*UDS THC                                                Within Groups 
                                                                   Total 
.090 .767 





*UDS THC                                               Within Groups 
                                                                   Total 
Tobacco User                                             Between Groups 
(combined) 
*UDS THC                                                Within Groups 
                                                                   Total 
.254 .618 
Alcohol User                                             Between Groups 
(combined) 
*UDS THC                                               Within Groups 
                                                                   Total 
.021 .885 







































ANOVA Results UDS THC (week 6) 
Variables F Sig. 
Payer *UDS THC                                     Between Groups 
(combined) 
                                                                   Within Groups 
                                                                   Total 
.002 .968 
Poverty Level Percentage                          Between Groups 
(combined) *UDS THC                                               Within 
Groups 
                                                                   Total      
.254 .618 
Age *UDS THC                                        Between Groups 
(combined) 
                                                                   Within Groups 
                                                                   Total 
.000 .997 
Marital Status *UDS THC                        Between Groups 
(combined) 
                                                                   Within Groups 
                                                                   Total 
.316 .579 
Education Level                                         Between Groups 
(combined) 
 *UDS THC                                               Within Groups 
                                                                   Total 
.202 .657 
Employed *UDS THC                              Between Groups 
(combined) 
                                                                   Within Groups 
                                                                   Total 
.017 .896 
Previous Treatment                                    Between Groups 
(combined) 
*UDS THC                                                Within Groups 
                                                                   Total 
.772 .387 
Treatment Prov                                          Between Groups 
(combined) 
*UDS THC                                                Within Groups 
                                                                   Total 
1.089 .306 
Family History                                           Between Groups 
(combined) 
*UDS THC                                                Within Groups 
                                                                   Total 
.090 .767 
Exercise                                                     Between Groups 
(combined) 




                                                                   Total 
Tobacco User                                             Between Groups 
(combined) 
*UDS THC                                                Within Groups 
                                                                   Total 
.254 .618 
Alcohol User                                             Between Groups 
(combined) 
*UDS THC                                               Within Groups 
                                                                   Total 
.021 .885 






































Table 5D  
 
ANOVA Results UDS Benzodiazepines (week 6) 
Variables F Sig. 
Payer *UDS Benzo                                    Between Groups 
(combined) 
                                                                   Within Groups 
                                                                   Total 
.320 .729 
Poverty Level Percentage                          Between Groups 
(combined) *UDS Benzo                                               Within 
Groups 
                                                                   Total      
.054 .948 
Age *UDS Benzo                                      Between Groups 
(combined) 
                                                                   Within Groups 
                                                                   Total 
1.771 .190 
Marital Status *UDS Benzo                      Between Groups 
(combined) 
                                                                   Within Groups 
                                                                   Total 
1.238 .306 
Education Level                                         Between Groups 
(combined) 
 *UDS Benzo                                              Within Groups 
                                                                   Total 
.228 .798 
Employed *UDS Benzo                             Between Groups 
(combined) 
                                                                   Within Groups 
                                                                   Total 
2.774 .081 
Previous Treatment                                    Between Groups 
(combined) 
*UDS Benzo                                               Within Groups 
                                                                   Total 
1.105 .346 
Treatment Prov                                          Between Groups 
(combined) 
*UDS Benzo                                                Within Groups 
                                                                   Total 
.112 .894 
Family History                                           Between Groups 
(combined) 
*UDS Benzo                                                Within Groups 
                                                                   Total 
1.017 .379 
Exercise                                                     Between Groups 
(combined) 




                                                                   Total 
Tobacco User                                             Between Groups 
(combined) 
*UDS Benzo                                                Within Groups 
                                                                   Total 
.054 .948 
Alcohol User                                             Between Groups 
(combined) 
*UDS Benzo                                               Within Groups 
                                                                   Total 
.952 .400 






































Table 6A  
 
Case Processing Summary of the *UDS Other-  











Gender *UDS other     22            67.4%          21                48.8%          43           
100% 





    22             67.4%         21                48.8%           43          
100% 
Age *UDS other     22             67.4%         21                48.8%           43          
100% 
Marital Status * UDS 
other 


















    22             67.4%         21                48.8%           43          
100% 
Family History of 
Drug Abuse* 
UDS other 
    18             55.8%         25                58.1%          43          100% 
Exercise * UDS other     22             51.2%         21                48.8%          43          100% 
Tobacco User *UDS 
other 
    22             51.2%         21                48.8%          43          100% 
Alcohol User *UDS 
other 
    20             46.5%         23                53.5%          43          100% 
 
 




Table 6B  
 
Case Processing Summary of the *UDS Oxycodone  











Gender *UDS oxyc     22            51.2%          21                48.8%          43           
100% 





    22             51.2%         21                48.8%           43          
100% 
Age *UDS oxyc     22             51.2%         21                48.8%           43          
100% 
Marital Status * oxy 
other 




    22             51.2%         21                48.8%           43          
100% 










    22             51.2%         21                48.8%           43          
100% 
Family History of 
Drug Abuse* 
UDS oxyc 
    18             41.9%         25                58.1%          43          100% 
Exercise * UDS oxyc     22             51.2%         21                48.8%          43          100% 
Tobacco User *UDS 
oxyc 
    22             51.2%         21                48.8%          43          100% 
Alcohol User *UDS 
oxyc 
    20             46.5%         23                53.5%          43          100% 
 







Table 6C  
 
Case Processing Summary of the *UDS Amphetamines 
 
 











Gender *UDS amph     22            51.2%          21                48.8%          43           
100% 





    22             51.2%         21                48.8%           43          
100% 
Age *UDS amph     22             51.2%         21                48.8%           43          
100% 
Marital Status * UDS 
amph 


















    22             51.2%         21                48.8%           43          
100% 
Family History of 
Drug Abuse* 
UDS amph 
    18             41.9%         25                58.1%          43          100% 
Exercise * UDS 
smph 
    22             51.2%         21                48.8%          43          100% 
Tobacco User *UDS 
amph 
    22             51.2%         21                48.8%          43          100% 
Alcohol User *UDS 
amph 
    20             46.5%         23                53.5%          43          100% 
 




Table 7A  
 
ANOVA Results UDS Other (week 10) 
Variables F Sig. 
Payer *UDS other                                     Between Groups 
(combined) 
                                                                   Within Groups 
                                                                   Total 
.025 .876 
Poverty Level Percentage                          Between Groups 
(combined) *UDS other                                               Within 
Groups 
                                                                   Total      
.284 .600 
Age *UDS other                                        Between Groups 
(combined) 
                                                                   Within Groups 
                                                                   Total 
.095 .761 
Marital Status *UDS other                        Between Groups 
(combined) 
                                                                   Within Groups 
                                                                   Total 
2.744 .113 
Education Level                                         Between Groups 
(combined) 
 *UDS other                                               Within Groups 
                                                                   Total 
.568 .460 
Employed *UDS other                              Between Groups 
(combined) 
                                                                   Within Groups 
                                                                   Total 
.705 .411 
Previous Treatment                                    Between Groups 
(combined) 
*UDS other                                               Within Groups 
                                                                   Total 
.034 .856 
Treatment Prov                                          Between Groups 
(combined) 
*UDS other                                                Within Groups 
                                                                   Total 
.885 .358 
Family History                                           Between Groups 
(combined) 
*UDS other                                                Within Groups 
                                                                   Total 
1.383 .257 
Exercise                                                     Between Groups 
(combined) 




                                                                   Total 
Tobacco User                                             Between Groups 
(combined) 
*UDS other                                                Within Groups 
                                                                   Total 
.284 .600 
Alcohol User                                             Between Groups 
(combined) 
*UDS other                                               Within Groups 
                                                                   Total 
.189 .669 








































ANOVA Results UDS Oxycodone (week 10) 
Variables F Sig. 
Payer *UDS oxyc                                     Between Groups 
(combined) 
                                                                   Within Groups 
                                                                   Total 
.885 .358 
Poverty Level Percentage                          Between Groups 
(combined) *UDS oxyc                                               Within 
Groups 
                                                                   Total      
.096 .760 
Age *UDS oxyc                                        Between Groups 
(combined) 
                                                                   Within Groups 
                                                                   Total 
1.917 .181 
Marital Status *UDS oxyc                        Between Groups 
(combined) 
                                                                   Within Groups 
                                                                   Total 
.856 .366 
Education Level                                         Between Groups 
(combined) 
 *UDS oxyc                                               Within Groups 
                                                                   Total 
.455 .508 
Employed *UDS oxyc                              Between Groups 
(combined) 
                                                                   Within Groups 
                                                                   Total 
1.212 .284 
Previous Treatment                                    Between Groups 
(combined) 
*UDS oxyc                                               Within Groups 
                                                                   Total 
1.212 .284 
Treatment Prov                                          Between Groups 
(combined) 
*UDS oxyc                                                Within Groups 
                                                                   Total 
.202 .658 
Family History                                           Between Groups 
(combined) 
*UDS oxyc                                                Within Groups 
                                                                   Total 
.622 .442 
Exercise                                                     Between Groups 
(combined) 




                                                                   Total 
Tobacco User                                             Between Groups 
(combined) 
*UDS oxyc                                                Within Groups 
                                                                   Total 
.096 .760 
Alcohol User                                             Between Groups 
(combined) 
*UDS oxyc                                               Within Groups 
                                                                   Total 
3.600 .074 






































Table 7C  
 
ANOVA Results UDS Amphetamine (week 10) 
Variables F Sig. 
Payer *UDS amph                                     Between Groups 
(combined) 
                                                                   Within Groups 
                                                                   Total 
.284 .600 
Poverty Level Percentage                          Between Groups 
(combined) *UDS amph                                              Within 
Groups 
                                                                   Total      
.045 .833 
Age *UDS amph                                        Between Groups 
(combined) 
                                                                   Within Groups 
                                                                   Total 
.100 .755 
Marital Status *UDS amph                        Between Groups 
(combined) 
                                                                   Within Groups 
                                                                   Total 
.399 .535 
Education Level                                         Between Groups 
(combined) 
 *UDS amph                                               Within Groups 
                                                                   Total 
.670 .423 
Employed *UDS amph                              Between Groups 
(combined) 
                                                                   Within Groups 
                                                                   Total 
.559 .463 
Previous Treatment                                    Between Groups 
(combined) 
*UDS amph                                               Within Groups 
                                                                   Total 
.559 .463 
Treatment Prov                                          Between Groups 
(combined) 
*UDS amph                                                Within Groups 
                                                                   Total 
.096 .760 
Family History                                           Between Groups 
(combined) 
*UDS amph                                                Within Groups 
                                                                   Total 
.622 .442 
Exercise                                                     Between Groups 
(combined) 




                                                                   Total 
Tobacco User                                             Between Groups 
(combined) 
*UDS amph                                                Within Groups 
                                                                   Total 
.045 .833 
Alcohol User                                             Between Groups 
(combined) 
*UDS amph                                               Within Groups 
                                                                   Total 
1.543 .230 







































Table 8A  
 
Treatment Options-Counseling, Counseling & Narcotics Anonymous (NA), NA, Excluded, 
Discharged, Relapse from the Program (n=43) 
Treatment  Number  
Onsite counseling 16 
Onsite counseling & NA 13 
NA 2 
Ex 
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The Confirmation of Ethical Standards (CES) has an IRB record number of 08-22-14-
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